Emergent BioSolutions | EBS - Current Assets


Emergent BioSolutions reported $679.5M in Current Assets for its fiscal quarter ending in December of 2023.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.06B 14.31M Dec/2025
Akebia Therapeutics USD 252.96M 5.38M Dec/2025
ALKERMES USD 1.93B 187.5M Dec/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Amarin USD 628.33M 21.52M Sep/2025
ANI Pharmaceuticals USD 753.12M 54.72M Dec/2025
BioMarin Pharmaceutical USD 3.95B 98.95M Dec/2025
Coherus Biosciences USD 206.71M 254.25M Dec/2025
Emergent BioSolutions USD 679.5M 41.3M Dec/2023
Exact Sciences USD 1.56B 34.88M Dec/2025
Exelixis USD 1.44B 41.03M Dec/2025
Glaxosmithkline GBP 23.98B 6.31B Sep/2025
Heron Therapeutics USD 229.4M 18.48M Sep/2025
Ionis Pharmaceuticals USD 2.99B 471.01M Dec/2025
Ironwood Pharmaceuticals USD 273.84M 82.09M Sep/2025
Lexicon Pharmaceuticals USD 145.08M 100.72M Jun/2025
Lonza CHF 5.44B 113M Dec/2024
Merck USD 47.56B 10.49B Sep/2025
Moderna USD 6.54B 54M Dec/2025
Myriad Genetics USD 344.8M 60.5M Sep/2025
Nektar Therapeutics USD 281.36M 94.79M Sep/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
Pacira USD 547.97M 14.78M Dec/2025
Pfizer USD 46.92B 3.22B Sep/2025
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Sanofi EUR 30.95B 3.09B Dec/2025
Sarepta Therapeutics USD 2.54B 184.37M Dec/2025
United Therapeutics USD 3.7B 208.5M Dec/2025
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025
Xoma USD 110.71M 5.78M Sep/2025